- Home
- VMAR vs CDT Comparison
VMAR vs CDT Comparison
Compare VMAR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMAR
- CDT
- Stock Information
- Founded
- VMAR 1995
- CDT 2019
- Country
- VMAR Canada
- CDT United States
- Employees
- VMAR N/A
- CDT N/A
- Industry
- VMAR Marine Transportation
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- VMAR Industrials
- CDT Health Care
- Exchange
- VMAR Nasdaq
- CDT Nasdaq
- Market Cap
- VMAR 5.1M
- CDT 5.3M
- IPO Year
- VMAR 2020
- CDT N/A
- Fundamental
- Price
- VMAR $6.62
- CDT $0.39
- Analyst Decision
- VMAR Strong Buy
- CDT
- Analyst Count
- VMAR 1
- CDT 0
- Target Price
- VMAR $2,700.00
- CDT N/A
- AVG Volume (30 Days)
- VMAR 35.6K
- CDT 768.1K
- Earning Date
- VMAR 07-14-2025
- CDT 05-15-2025
- Dividend Yield
- VMAR N/A
- CDT N/A
- EPS Growth
- VMAR N/A
- CDT N/A
- EPS
- VMAR N/A
- CDT N/A
- Revenue
- VMAR $1,612,492.00
- CDT N/A
- Revenue This Year
- VMAR $120.43
- CDT N/A
- Revenue Next Year
- VMAR N/A
- CDT N/A
- P/E Ratio
- VMAR N/A
- CDT N/A
- Revenue Growth
- VMAR N/A
- CDT N/A
- 52 Week Low
- VMAR $4.04
- CDT $0.51
- 52 Week High
- VMAR $1,039.50
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- VMAR 52.65
- CDT 31.63
- Support Level
- VMAR $6.28
- CDT $0.38
- Resistance Level
- VMAR $7.40
- CDT $0.41
- Average True Range (ATR)
- VMAR 0.64
- CDT 0.04
- MACD
- VMAR 0.05
- CDT 0.01
- Stochastic Oscillator
- VMAR 61.05
- CDT 9.89
About VMAR Vision Marine Technologies Inc.
Vision Marine Technologies Inc is in the business of designing and manufacturing electric outboard powertrain systems, power boats, and related technology and the renting of electric boats. The different models of the powerboats and electric boats manufactured by the company include Bruce 22, Fantail 217, Volt 180, and others. The company operates in two reportable business segments; Sale of electric boats and Rental of electric boats. The majority of the revenue for the company is generated from the Sale of electric boats segment. Geographically, the company generates revenue from its business in Canada, USA and other countries. A substantial portion of the overall revenue is generated from its business in USA.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.